<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948035</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XVII</org_study_id>
    <secondary_id>2017-001616-11</secondary_id>
    <nct_id>NCT03948035</nct_id>
  </id_info>
  <brief_title>Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM</brief_title>
  <official_title>Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a
      lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III
      trials in MM patients. One phase III trial in MM patients with one to three prior lines of
      therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to
      significantly prolong PFS in this patient cohort with a greater proportion of patients in at
      least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of
      infusion-related reactions with this specific moAb was very low, with an overall rate of 10%
      in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related
      reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related
      reactions. Of particular interest is the observation in this trial, that response and PFS
      were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and
      translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other
      drug-based approaches.

      The investigators assume that incorporating the moAb into the KRd triple induction regimen
      should result in an even higher rate of deep (negative for MRD in conjunction with at least
      very good partial response [VGPR] as defined by the International Myeloma Working Group
      [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential
      interference of elotuzumab with serum immune fixation, the investigators chose VGPR rather
      than complete response (CR) to exclude false-positive immunofixation results. Furthermore the
      investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS
      further.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is a cancer originating from the antibody-secreting plasma cell and
      characterized by abnormal accumulation of clonal plasma cells in bone marrow. In Europe, 3.8
      new cases of MM and 2.2 deaths per 100,000 individuals (age-standardized rate) due to MM were
      estimated in 2012.

      Treatment options for myeloma patients have markedly improved during the last decades.

      For frontline treatment, high-dose myeloablative chemotherapy followed by reinfusion of
      autologous peripheral blood stem cells has been a standard of care since 1996. Introduction
      of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and
      lenalidomide led to improvement in remission rates and survival in newly diagnosed patients.
      However, high-dose chemotherapy remains essential for achievement of long-lasting remissions
      even in the era of novel agents.

      While high-dose melphalan chemotherapy (HDT) plus autologous stem cell transplant (ASCT)
      remains a standard in eligible, medically fit subjects, defining an optimal pre- and post HDT
      approach is subject to rapidly evolving novel-compound based options. In 2010, a group from
      the U.S. presented results on the combination of lenalidomide, bortezomib, and dexamethasone
      (VRd) in newly diagnosed patients with an overall response rate of 98%, however without
      systematic consolidation by HDT. The next-generation proteasome inhibitor carfilzomib is more
      active and very well tolerated in terms of peripheral neuropathy and gastrointestinal adverse
      effects. A randomized phase III trial in pretreated myeloma patients found the triple regimen
      of carfilzomib and lenalidomide/dexamethasone (Rd) to be superior to standard-Rd in terms of
      depth of response; progression-free survival (PFS) and, most importantly, overall survival
      (OS). At the 2015 annual meetings of the American Society of Clinical Oncology as well as the
      European Society of Hematology, this regimen (KRd) was found to be exceptionally effective in
      a phase 2 trial when given in newly diagnosed patients in a prolonged fashion: patients
      received four KRd induction cycles prior to HDT. The latter was followed by an additional 4
      consolidation and 8 maintenance cycles with KRd, followed by lenalidomide maintenance
      thereafter. The most appealing effect was the high rate of deep remissions: stringent
      complete response (sCR) rate increased from 22% following 4 x KRd and HDT to more than 80%
      following all 18 cycles. Notably, the vast majority of patients in sCR also were negative for
      minimal residual disease (MRD) as assessed by 10-color flow cytometry. MRD negativity
      probably has a major impact on long-term disease control as was recently shown in a French
      prospective trial investigating in the combination of VRd prior and post HDT followed by
      lenalidomide maintenance.

      Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a
      lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III
      trials in MM patients. One phase III trial in MM patients with one to three prior lines of
      therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to
      significantly prolong PFS in this patient cohort with a greater proportion of patients in at
      least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of
      infusion-related reactions with this specific moAb was very low, with an overall rate of 10%
      in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related
      reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related
      reactions. Of particular interest is the observation in this trial, that response and PFS
      were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and
      translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other
      drug-based approaches.

      The investigators assume that incorporating the moAb into the KRd triple induction regimen
      should result in an even higher rate of deep (negative for MRD in conjunction with at least
      very good partial response [VGPR] as defined by the International Myeloma Working Group
      [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential
      interference of elotuzumab with serum immune fixation,the investigators chose VGPR rather
      than complete response (CR) to exclude false-positive immunofixation results. Furthermore the
      investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS
      further.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction phase</measure>
    <time_frame>At the end of Cycle 6 (168 days for all cycles plus up to 36 days)</time_frame>
    <description>MRD negativity rate (%) as assessed by flow-cytometry in patients with VGPR or better response according to IMWG criteria following six cycles of induction treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance phase</measure>
    <time_frame>3 years from randomisation</time_frame>
    <description>Determination of progression-free survival (PFS) following randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of long-term efficacy (1)</measure>
    <time_frame>10 years</time_frame>
    <description>Overall response rate (%) to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of long-term efficacy (2)</measure>
    <time_frame>10 years</time_frame>
    <description>Overall survival (months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of long-term efficacy (3)</measure>
    <time_frame>10 years</time_frame>
    <description>Quality of Life (Units on Scale; Unit range from 0 to 100; Units calculated via linear transformation of raw score (RS) values from scale with single-item measure from 1 to 7 on EORTC QLQ-C30 questionnaire equivalent; Formular for transformation: Unit = {(RS-1)/6}x100)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <other_name>Empliciti®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <other_name>Fortecortin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous stem cell transplant</intervention_name>
    <description>autologous stem cell transplant</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for autologous stem cell transplantation (ASCT)

          -  Patient must not have been previously treated with any prior systemic therapy for the
             treatment of multiple myeloma (only dexamethasone at a cumulative dose of 320 mg;
             plasmapheresis/dialysis without concomitant chemotherapy,local irradiation of bone
             lesions; and surgical intervention permitted as pretreatment)

          -  Newly diagnosed multiple myeloma according to the IMWG updated criteria42: Clonal bone
             marrow plasma cells ≥ 10% or biopsy proven bony or extramedullary plasmacytoma and any
             one or more of the following myeloma defining events:

          -  Evidence of end organ damage that can be attributed to the underlying plasma cell
             proliferative disorder, specifically:

               -  Hypercalcaemia: serum calcium &gt; 0.25 mmol/L (&gt; 1 mg/dL) higher than the upper
                  limit of normal or &gt; 2.75 mmol/L (&gt; 11 mg/dL)

               -  Renal insufficiency: creatinine clearance &lt; 40 mL per min or serum creatinine &gt;
                  177 μmol/L (&gt; 2 mg/dL)

               -  Anaemia: haemoglobin value of &gt; 2 g/dL below the lower limit of normal, or a
                  haemoglobin value &lt; 10 g/dL

               -  Bone lesions: one or more osteolytic lesions on skeletal radiography,computed
                  tomography (CT), or PET-CT

          -  Any one or more of the following markers of malignancy:

               -  Clonal bone marrow plasma cell percentage ≥ 60%

               -  Involved: uninvolved serum free light chain ratio ≥ 100, provided the absolute
                  level of the involved light chain is at least 100 mg/L

               -  One or more focal lesions of at least 5mm or greater in size on MRI studies

          -  Measurable disease parameters as follows:

          -  Serum monoclonal paraprotein (M-component) level ≥ 1 g/dL and/or urine M-protein level
             ≥ 200 mg/24 hours or

          -  In case of IgA myeloma: Serum monoclonal paraprotein level ≥ 0.5 g/dL and/or urine
             M-protein level ≥ 200 mg/24 hours or

          -  For patients with no detectable M-component: Serum FLC Assay: Involved FLC level ≥ 10
             mg/dL (≥ 100 mg/L) provided serum FLC ratio is abnormal

          -  ECOG Performance Status ≤ 2

          -  Laboratory test results within these ranges:

          -  White blood cell count ≥ 2 x 109/L

          -  Absolute neutrophil (ANC) count ≥ 1.0 x 109/L

          -  Platelet count ≥ 75 x 109/L

          -  Haemoglobin &gt; 8 g/dL

          -  Calculated creatinine clearance (according to MDRD) ≥ 30 mL/minute

          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 x ULN

          -  Corrected serum calcium level &lt; 3.5 mmol/L (&lt; 14 mg/dL)

          -  Patient's legal capacity to consent to study participation

          -  Patients capable to understand the purposes and risks of the study, who are willing
             and able to participate in the study and from whom written and dated informed consent
             to participate in the study has been obtained.

          -  All females

               -  must acknowledge to have understood the hazards lenalidomide can cause to an
                  unborn fetus and the necessary precautions associated with the use of
                  lenalidomide.

               -  must use adequate contraception and agree to use two reliable forms of
                  contraception simultaneously or to practice complete abstinence

               -  must agree to have medically supervised pregnancy tests on a regular basis

               -  must agree to abstain from breastfeeding while taking lenalidomide, carfilzomib
                  and elotuzumab and for at least 28 days after the last dose of lenalidomide,
                  carfilzomib, and elotuzumab.

          -  Male subjects must

               -  practice complete abstinence or use a condom during sexual contact with a
                  pregnant female or a female with child bearing potential while taking
                  lenalidomide, carfilzomib, and elotuzumab.

               -  not donate semen or sperm

          -  All subjects must

               -  agree to abstain from donating blood while taking lenalidomide, during dose
                  interruptions and for at least 28 days after the last dose of lenalidomide.

               -  agree never to give lenalidomide to another person.

               -  agree to return all unused lenalidomide capsules to the investigator (with
                  exception of prescribed lenalidomide capsules)

               -  be aware that no more than a 28-day lenalidomide supply may be dispensed with
                  each cycle of lenalidomide during induction and consolidation therapy and be
                  prescribed during maintenance therapy.

        Exclusion Criteria:

          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,

          -  monoclonal protein, and skin changes)

          -  Waldenström's macroglobulinemia or IgM myeloma

          -  Plasma cell leukemia (&gt; 2.0 x 109/L circulating plasma cells by standard differential
             blood count)

          -  Pregnant, breast-feeding females, FCBPs and males who are unwilling to comply with the
             lenalidomide Pregnancy Prevention Risk Management Plan.

          -  Patients with high cardiovascular risk, including but not limited to history of
             myocardial infarction or coronary stenting in the past 6 months; NYHA Class III or IV
             heart failure, uncontrolled angina, uncontrolled hypertension, severe uncontrolled
             arrhythmias

          -  Prior cerebral vascular accident (CVA) with persistent neurological deficit

          -  Active infection

          -  Known HIV-seropositivity, active or chronic hepatitis A, B, C or D-infection
             (including patients who are tested anti-HBC positive and/or HBsAg positive).

          -  Any other severe concomitant disease or disorder, including the presence of laboratory
             abnormalities, which places the subject at unacceptable risk or which could influence
             patient's ability to participate in the study and his/her safety during the study or
             interfere with interpretation of study results.

          -  Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14
             days before enrollment

          -  Major surgery within 4 weeks prior to randomization

          -  Any systemic anti-myeloma therapy within 4 weeks of randomization except a max.
             cumulative dose of 320 mg auf dexamethasone.

          -  Any prior or concurrent malignancy other than multiple myeloma.

          -  Exceptions include patients who have been disease-free for at least five years before
             study entry or patients with adequately treated and completely resected basal cell or
             squamous cell skin cancer, in situ cervical, breast or prostate cancer.

          -  Known hypersensitivity to carfilzomib, lenalidomide, and elotuzumab or to any of the
             excipients of carfilzomib, lenalidomide, and elotuzumab or to any other component of
             any study drug formulation

          -  Participation in any other clinical trial or treatment with any experimental drug or
             other experimental therapy within 28 days before enrolment to the study or during
             study participation until the end of treatment visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Knop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuezburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hermann Einsele, MD</last_name>
    <phone>+49 (0)931 201</phone>
    <phone_ext>40001</phone_ext>
    <email>Einsele_H@ukw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Knop, MD</last_name>
    <phone>+49 (0)931 201</phone>
    <phone_ext>40013</phone_ext>
    <email>Knop_S@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univ. Klinikum Krems</name>
      <address>
        <city>Krems</city>
        <state>Lower Austria</state>
        <zip>A-3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klaus Podar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum St. Pölten</name>
      <address>
        <city>St. Polten</city>
        <state>Lower Austria</state>
        <zip>A-3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Pichler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH-Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siegfried Sormann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Normann Steiner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clemens Schmitt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kühr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Rankweil-Feldkirch</name>
      <address>
        <city>Rankweil</city>
        <state>Vorarlberg</state>
        <zip>A-6830</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hartmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Meduni Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria-Theresa Krauth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Meduni Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hermine Agis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Zojer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Engelhardt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb</name>
      <address>
        <city>Mutlangen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Dechow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonieklinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Greiner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Hoferer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Kull, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Schwarzwald-Alb</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Köchling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gesundgheitszentrum St. Marien</name>
      <address>
        <city>Amberg</city>
        <state>Bavaria</state>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Hackanson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg</name>
      <address>
        <city>Bamberg</city>
        <state>Bavaria</state>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Seggewiß-Bernhardt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <state>Bavaria</state>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kiani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten-Oberallgäu</name>
      <address>
        <city>Kempten</city>
        <state>Bavaria</state>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Langer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80634</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Hentrich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Theurich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bassermann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nuremberg</city>
        <state>Bavaria</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Reichle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <state>Bavaria</state>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Zettl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik II</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Knop, MD</last_name>
      <phone>+49 (0)931 201</phone>
      <phone_ext>40013</phone_ext>
      <email>Knop_S@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivana von Metzler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Jung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Könecke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Metzner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Pomerania</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian-Andreas Schmidt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Pomerania</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Böttcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Pomerania</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Günther, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Bethel</name>
      <address>
        <city>Bielefeld</city>
        <state>North Rhine-Westphalia</state>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Weißinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <state>North Rhine-Westphalia</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Meyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Barbara-Klinik Hamm</name>
      <address>
        <city>Hamm</city>
        <state>North Rhine-Westphalia</state>
        <zip>59075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Dürk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Reusch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marien-Krankenhaus</name>
      <address>
        <city>Siegen</city>
        <state>North Rhine-Westphalia</state>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Naumann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Mittelrhein</name>
      <address>
        <city>Koblenz</city>
        <state>Rhineland-Palatinate</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Breitbarth-Girmscheid, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinga Ligeti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolleschak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolin Trautmann-Grill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Pönisch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Menzel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Schub, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svenja Kopelke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <state>Thuringia</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekkehard Eigendorff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Schiller-Universität Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie von Lilienfeld-Toal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor-Wolfgang Blau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Fuhrmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annegret Kunitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Bormann, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>autologous stem cell transplant</keyword>
  <keyword>Elotuzumab</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

